Australian Study: Smart Insulin Pumps Help Restore Dangerous Low Blood Sugar Warning Signs

A study from Australia has uncovered promising evidence that advanced hybrid closed-loop (HCL) insulin pump systems may do more than just manage blood sugar — they may actually help restore the body's ability to detect dangerous low blood sugar episodes in people who have lost that critical warning ability.

What Is Impaired Hypoglycemia Awareness — And Why Is It So Dangerous?

Most people with Type 1 diabetes can feel when their blood sugar drops too low — they sweat, shake, or feel their heart race. But some long-term Type 1 patients develop a condition called impaired awareness of hypoglycemia (IAH), where those warning signals fade or disappear entirely. This is extremely dangerous: without internal warnings, a blood sugar crash can lead to seizures, loss of consciousness, or even death before the person realizes anything is wrong.

Researchers at the Department of Medicine, University of Melbourne focused specifically on this high-risk group — adults who scored at or above 1047 on the Edmonton HYPO Score, a validated tool measuring severe hypoglycemia risk. These were patients with some of the most dangerous diabetes profiles in clinical practice.

What the Study Found

Nine adult participants with Type 1 diabetes and severe IAH were randomized over 26 weeks to either the MiniMed™ 670G hybrid closed-loop system (which automatically adjusts insulin delivery based on continuous glucose readings) or standard therapy — either multiple daily injections or a traditional insulin pump — without any continuous glucose monitoring (CGM).

The results were striking:

• Time-in-Range (TIR) improved dramatically: HCL users spent 70% of their time in the target blood sugar range of 70–180 mg/dL, compared to just 48% for standard therapy patients. Current American Diabetes Association (ADA) guidelines recommend a TIR goal of at least 70% for most Type 1 adults — meaning HCL users hit that benchmark while the standard therapy group fell dangerously short.
• Hypoglycemia episodes were shorter: When lows did occur, HCL users recovered faster — 30 minutes vs. 50 minutes for standard therapy patients.
• Glycemia Risk Index (GRI) was significantly lower: The HCL group scored 38.1 vs. 70.8 for the control group, reflecting an overall safer blood sugar profile.
• Hormonal warning responses partially recovered: After 6 months on HCL, patients showed stronger dopamine and growth hormone responses during low blood sugar events — hormones the body uses to trigger awareness and corrective action. This suggests the automated system may allow the body's own warning mechanisms to begin recovering.

Why This Matters for US Patients

In the United States, an estimated 17–25% of Type 1 diabetes patients develop some degree of impaired hypoglycemia awareness over time. For these individuals, standard diabetes management carries life-threatening risks that most guidelines don't fully address. The MiniMed 670G system used in this study is FDA-approved and available in the US, meaning these findings are directly applicable to American patients right now.

Importantly, this Australian research adds to a growing global body of evidence suggesting that HCL systems aren't just a convenience — for high-risk patients, they may be a life-saving medical intervention that gives the body a chance to heal its own warning system.

If you or a loved one has been told you no longer feel your lows, speak with your endocrinologist about whether a hybrid closed-loop system may be appropriate for your care plan.

Study Citation

Lee, Gooley, Obeyesekere et al. "Hybrid Closed Loop in Adults With Type 1 Diabetes and Severely Impaired Hypoglycemia Awareness." Journal of Diabetes Science and Technology, 2025. PMID: 38613225. DOI: 10.1177/19322968241245627